I guess you could start with the jersey he has on - who is his team, i.e. where does he live?
ICYMI: Wow! Here's your good news for the evening "New cancer drug 93% effective w pediatric patients," + 75% success in adults. Called "unprecedented" by researchers.
By Allen Cone | March 30, 2018 at 1:52 PM
The drug larotrectinib was effective in 93 percent of pediatric patients tested in a Phase 1 clincial trial, according to researchers at the University of Texas Southwestern. Photo by Bill Branson/National Cancer Institute
March 30 (UPI) – A new cancer drug called larotrectinib was effective in 93 percent of pediatric patients tested in a Phase 1 clincial trial, researchers announced.
Researchers at University of Texas' Southwestern's Simmons Cancer Center in Dallas tested larotrectinib, which targets a fused gene called TRK found in many types of cancer in a clinical trial. The findings were published Thursday in The Lancet.
Larotrectinib is the first cancer drug to receive Food and Drug Administration breakthrough therapy designation for patients with a specific fusion of two genes in the cancer cell regardless of the type of cancer.
These TRK fusions occur in a few common adult cancers, but they appear frequently in rare pediatric cancers, including infantile fibrosarcoma, cellular congenital mesoblastic nephroma and papillary thyroid cancer.
https://www.upi.com/Health_News/2018/03/30/New-cancer-drug-93-percent-effective-with-pediatric-patients/5971522419450/?utm_source=sec&utm_campaign=sl&utm_medium=5